Full Text of PDF (727k)
Article in Japanese
Abstract
Case Report
Dabigatran etexilate-induced eosinophilic pneumonia
Akifumi Fujitaa Nao Inamia Hiroki Asizawaa Tomoyuki Tuchiyaa Atsushi Yositomia Masafumi Masudaa Takafumi Sudab Kingo Chidab
aDepartment of Respiratory Medicine, Shizuoka City Shimizu Hospital
bSecond Department of Internal Medicine, Hamamatsu University School of Medicine
ABSTRACT
An 81-year-old man was admitted to our hospital because of infiltrative shadow of his chest X-ray, which did not improve with the administration of antibiotics. Past medical history included nonvalvular atrial fibrillation (Af). He had been started with dabigatran etexilate for nonvalvular Af one month before admission, and just after administration cough and phlegm emerged. Bronchoalveolar lavage revealed elevated eosinophil of 40%. We diagnosed him as dabigatran etexilate-induced eosinophilic pneumonia. His respiratory condition and infiltative shadow on chest X-ray improved only with cessation of the drug, without the use of steroids. Dabigatran etexilate is a new drug that in March 2011 was approved in Japan. Although reports on dabigatran etexilate-induced eosinophilic pneumonia cannot be found yet, the possibility of drug-induced lung injury by dagigatran etexilate must be kept in mind.
KEYWORDS
Dabigatran etexilate Drug-induced lung injury Eosiophilic pneumonia
Received 14 Nov 2012 ／ Accepted 5 Mar 2013
AJRS, 2(4): 414-418, 2013
Copyright © The Japanese Respiratory Society All Rights Reserved.